Cristin-resultat-ID: 1573783
Sist endret: 5. februar 2019, 14:33
NVI-rapporteringsår: 2018
Resultat
Vitenskapelig artikkel
2018

Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials

Bidragsytere:
  • Tinne Laurberg
  • Trine Tramm
  • Torsten Nielsen
  • Jan Alsner
  • Silje Nord
  • Simen Myhre
  • mfl.

Tidsskrift

Acta Oncologica
ISSN 0284-186X
e-ISSN 1651-226X
NVI-nivå 1

Om resultatet

Vitenskapelig artikkel
Publiseringsår: 2018
Trykket: 2018
Volum: 57
Hefte: 1
Sider: 38 - 43

Importkilder

Scopus-ID: 2-s2.0-85034852368

Beskrivelse Beskrivelse

Tittel

Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials

Sammendrag

BACKGROUND: The study of the intrinsic molecular subtypes of breast cancer has revealed differences among them in terms of prognosis and response to chemotherapy and endocrine therapy. However, the ability of intrinsic subtypes to predict benefit from adjuvant radiotherapy has only been examined in few studies. METHODS: Gene expression-based intrinsic subtyping was performed in 228 breast tumors collected from two independent post-mastectomy clinical trials (British Columbia and the Danish Breast Cancer Cooperative Group 82b trials), where pre-menopausal patients with node-positive disease were randomized to adjuvant radiotherapy or not. All patients received adjuvant chemotherapy and a subgroup of patients underwent ovarian ablation. Tumors were classified into intrinsic subtypes: Luminal A, Luminal B, HER2-enriched, Basal-like and Normal-like using the research-based PAM50 classifier. RESULTS: In the British Columbia study, patients treated with radiation had an overall significant lower incidence of locoregional recurrence compared to the controls. For Luminal A tumors the risk of loco-regional recurrence was low and was further lowered by adjuvant radiation. These findings were validated in the DBCG 82b study. The individual data from the two cohorts were merged, the hazard ratio (HR) for loco-regional recurrence associated with giving radiation was 0.34 (0.19 to 0.61) overall and 0.12 (0.03 to 0.52) for Luminal A tumors. CONCLUSIONS: In both postmastectomy trials, patients with Luminal A tumors turned out to have a significant lower incidence of loco-regional recurrence when randomized to adjuvant radiotherapy, leaving no indication to omit postmastectomy adjuvant radiation in pre-menopausal high-risk patients with Luminal A tumors. It was not possible to evaluate the effect of radiotherapy among the other subtypes because of limited sample sizes.

Bidragsytere

Tinne Laurberg

  • Tilknyttet:
    Forfatter
    ved Århus Universitetshospital

Trine Tramm

  • Tilknyttet:
    Forfatter
    ved Århus Universitetshospital

Torsten O. Nielsen

Bidragsyterens navn vises på dette resultatet som Torsten Nielsen
  • Tilknyttet:
    Forfatter
    ved BC Cancer Agency

Jan Alsner

  • Tilknyttet:
    Forfatter
    ved Århus Universitetshospital

Silje Nord

  • Tilknyttet:
    Forfatter
    ved Seksjon for kreftgenetikk ved Oslo universitetssykehus HF
1 - 5 av 15 | Neste | Siste »